Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cerebrolysin After Reperfusion in Extended-Window Endovascular Thrombectomy: A Multicenter Randomized Controlled Trial

NCT06339411 is registered in ClinicalTrials.gov with Chang Gung Memorial Hospital as lead sponsor.

NCT NCT06339411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06339411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cerebrolysin After Reperfusion in Extended-Window Endovascular Thrombectomy: A Multicenter Randomized Controlled Trial
Lead sponsor
Chang Gung Memorial Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
December 31, 2030
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke